Piper Sandler’s Yasmeen Rahimi sees great potential in Mirum Pharmaceuticals (NASDAQ: MIRM) on a higher-than-expected Alagille Syndrome (ALGS) market. Rahimi ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE